{"transactions":[{"id":953801,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"2020 Performance Stock Units","published_at":"2026-01-05T22:54:51.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":false,"shares":28570,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance restricted stock unit (\"PSU\") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each performance restricted stock unit (\"PSU\") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each performance restricted stock unit (\"PSU\") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company."}],"balance_after":595077,"derivative":{"underlying":"Common Stock","underlying_shares":28570},"source":{"system":"sec-edgar","filing":"0001226690-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000122669026000002/edgardoc.xml","form_type":"4"}},{"id":953800,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2026-01-05T22:54:51.000Z","date":"2025-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":28570,"price":772.09,"value":22058611.3,"ownership":{"direct":true},"balance_after":310460,"source":{"system":"sec-edgar","filing":"0001226690-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000122669026000002/edgardoc.xml","form_type":"4"}},{"id":953799,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2026-01-05T22:54:51.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":true,"shares":28570,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":339030,"source":{"system":"sec-edgar","filing":"0001226690-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000122669026000002/edgardoc.xml","form_type":"4"}},{"id":973338,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-12-11T21:27:23.000Z","date":"2025-12-09","kind":"exercise","planned":false,"acquired":false,"shares":146815,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award vested in four equal annual installments, commencing one year after the date of grant."}],"balance_after":0,"derivative":{"exercise_price":555.67,"expiration_date":"2025-12-16","underlying":"Common Stock","underlying_shares":146815},"source":{"system":"sec-edgar","filing":"0001226690-25-000005","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000122669025000005/edgardoc.xml","form_type":"4"}},{"id":973337,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2025-12-11T21:27:23.000Z","date":"2025-12-09","kind":"tax_withholding","planned":false,"acquired":false,"shares":131874,"price":701.51,"value":92510929.74,"ownership":{"direct":true},"balance_after":310460,"source":{"system":"sec-edgar","filing":"0001226690-25-000005","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000122669025000005/edgardoc.xml","form_type":"4"}},{"id":973336,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2025-12-11T21:27:23.000Z","date":"2025-12-09","kind":"exercise","planned":false,"acquired":true,"shares":146815,"price":555.67,"value":81580691.05,"ownership":{"direct":true},"balance_after":442334,"source":{"system":"sec-edgar","filing":"0001226690-25-000005","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000122669025000005/edgardoc.xml","form_type":"4"}},{"id":1482641,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-06-12T20:10:49.000Z","date":"2024-06-10","kind":"gift","planned":false,"acquired":true,"shares":37900,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Children"},"balance_after":56048,"source":{"system":"sec-edgar","filing":"0001883850-24-000033","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000033/edgardoc.xml","form_type":"4"}},{"id":1482640,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-06-12T20:10:49.000Z","date":"2024-06-10","kind":"gift","planned":false,"acquired":false,"shares":75799,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by 2022 GRAT II"},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001883850-24-000033","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000033/edgardoc.xml","form_type":"4"}},{"id":1512831,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:06:52.000Z","date":"2024-05-16","kind":"sale","planned":true,"acquired":false,"shares":379,"price":978.18,"value":370730.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Represents volume-weighted average price of sales of 379 shares of Company stock on May 16, 2024 at prices ranging from $978.07 to $978.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 16, 2024 at each separate price."}],"balance_after":786383,"source":{"system":"sec-edgar","filing":"0001968202-24-000094","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000094/edgardoc.xml","form_type":"4"}},{"id":1512830,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:06:52.000Z","date":"2024-05-16","kind":"sale","planned":true,"acquired":false,"shares":1227,"price":977.38,"value":1199245.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents volume-weighted average price of sales of 1,227 shares of Company stock on May 16, 2024 at prices ranging from $977.02 to $977.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 16, 2024 at each separate price."}],"balance_after":786762,"source":{"system":"sec-edgar","filing":"0001968202-24-000094","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000094/edgardoc.xml","form_type":"4"}},{"id":1512829,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:06:52.000Z","date":"2024-05-16","kind":"sale","planned":true,"acquired":false,"shares":4886,"price":976.52,"value":4771276.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents volume-weighted average price of sales of 4,886 shares of Company stock on May 16, 2024 at prices ranging from $976.00 to $976.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 16, 2024 at each separate price."}],"balance_after":787989,"source":{"system":"sec-edgar","filing":"0001968202-24-000094","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000094/edgardoc.xml","form_type":"4"}},{"id":1512828,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:06:52.000Z","date":"2024-05-16","kind":"sale","planned":true,"acquired":false,"shares":9242,"price":975.48,"value":9015386.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents volume-weighted average price of sales of 9,242 shares of Company stock on May 16, 2024 at prices ranging from $975.00 to $975.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 16, 2024 at each separate price."}],"balance_after":792875,"source":{"system":"sec-edgar","filing":"0001968202-24-000094","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000094/edgardoc.xml","form_type":"4"}},{"id":1512827,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:06:52.000Z","date":"2024-05-16","kind":"sale","planned":true,"acquired":false,"shares":7611,"price":974.51,"value":7416995.61,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents volume-weighted average price of sales of 7,611 shares of Company stock on May 16, 2024 at prices ranging from $974.00 to $974.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 16, 2024 at each separate price."}],"balance_after":802117,"source":{"system":"sec-edgar","filing":"0001968202-24-000094","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000094/edgardoc.xml","form_type":"4"}},{"id":1512826,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:06:52.000Z","date":"2024-05-16","kind":"sale","planned":true,"acquired":false,"shares":2653,"price":973.8,"value":2583491.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents volume-weighted average price of sales of 2,653 shares of Company stock on May 16, 2024 at prices ranging from $973.20 to $973.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 16, 2024 at each separate price."}],"balance_after":809728,"source":{"system":"sec-edgar","filing":"0001968202-24-000094","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000094/edgardoc.xml","form_type":"4"}},{"id":1512825,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:06:52.000Z","date":"2024-05-16","kind":"sale","planned":true,"acquired":false,"shares":790,"price":972.22,"value":768053.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 790 shares of Company stock on May 16, 2024 at prices ranging from $972.00 to $972.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 16, 2024 at each separate price."}],"balance_after":812381,"source":{"system":"sec-edgar","filing":"0001968202-24-000094","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000094/edgardoc.xml","form_type":"4"}},{"id":1512824,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:06:52.000Z","date":"2024-05-16","kind":"sale","planned":true,"acquired":false,"shares":4922,"price":971.56,"value":4782018.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 4,922 shares of Company stock on May 16, 2024 at prices ranging from $971.05 to $971.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 16, 2024 at each separate price."}],"balance_after":813171,"source":{"system":"sec-edgar","filing":"0001968202-24-000094","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000094/edgardoc.xml","form_type":"4"}},{"id":1512823,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:06:52.000Z","date":"2024-05-16","kind":"sale","planned":true,"acquired":false,"shares":4669,"price":970.26,"value":4530143.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 4,669 shares of Company stock on May 16, 2024 at prices ranging from $970.00 to $970.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 16, 2024 at each separate price."}],"balance_after":818093,"source":{"system":"sec-edgar","filing":"0001968202-24-000094","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000094/edgardoc.xml","form_type":"4"}},{"id":1512822,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:06:52.000Z","date":"2024-05-16","kind":"sale","planned":true,"acquired":false,"shares":9501,"price":969.39,"value":9210174.39,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 9,501 shares of Company stock on May 16, 2024 at prices ranging from $969.03 to $969.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 16, 2024 at each separate price."}],"balance_after":822762,"source":{"system":"sec-edgar","filing":"0001968202-24-000094","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000094/edgardoc.xml","form_type":"4"}},{"id":1512821,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:06:52.000Z","date":"2024-05-16","kind":"sale","planned":true,"acquired":false,"shares":3213,"price":968.44,"value":3111597.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 3,213 shares of Company stock on May 16, 2024 at prices ranging from $968.04 to $968.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 16, 2024 at each separate price."}],"balance_after":832263,"source":{"system":"sec-edgar","filing":"0001968202-24-000094","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000094/edgardoc.xml","form_type":"4"}},{"id":1512820,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:06:52.000Z","date":"2024-05-16","kind":"sale","planned":true,"acquired":false,"shares":907,"price":967.4,"value":877431.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 907 shares of Company stock on May 16, 2024 at prices ranging from $967.13 to $967.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 16, 2024 at each separate price."}],"balance_after":835476,"source":{"system":"sec-edgar","filing":"0001968202-24-000094","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000094/edgardoc.xml","form_type":"4"}},{"id":1512816,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:04:51.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":120,"price":989.14,"value":118696.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F25","text":"Represents volume-weighted average price of sales of 120 shares of Company stock on May 15, 2024 at prices ranging from $989.01 to $989.28. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":836383,"source":{"system":"sec-edgar","filing":"0001968202-24-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000093/edgardoc.xml","form_type":"4"}},{"id":1512815,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:04:51.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":373,"price":988.36,"value":368658.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F24","text":"Represents volume-weighted average price of sales of 373 shares of Company stock on May 15, 2024 at prices ranging from $988.00 to $988.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":836503,"source":{"system":"sec-edgar","filing":"0001968202-24-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000093/edgardoc.xml","form_type":"4"}},{"id":1512814,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:04:51.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":182,"price":987.38,"value":179703.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F23","text":"Represents volume-weighted average price of sales of 182 shares of Company stock on May 15, 2024 at prices ranging from $987.03 to $987.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":836876,"source":{"system":"sec-edgar","filing":"0001968202-24-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000093/edgardoc.xml","form_type":"4"}},{"id":1512813,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:04:51.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":442,"price":986.4,"value":435988.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F22","text":"Represents volume-weighted average price of sales of 442 shares of Company stock on May 15, 2024 at prices ranging from $986.30 to $986.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":837058,"source":{"system":"sec-edgar","filing":"0001968202-24-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000093/edgardoc.xml","form_type":"4"}},{"id":1512812,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:04:51.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":647,"price":985.62,"value":637696.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F21","text":"Represents volume-weighted average price of sales of 647 shares of Company stock on May 15, 2024 at prices ranging from $985.11 to $985.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":837500,"source":{"system":"sec-edgar","filing":"0001968202-24-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000093/edgardoc.xml","form_type":"4"}},{"id":1512811,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:04:51.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":53,"price":984.02,"value":52153.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."}],"balance_after":838147,"source":{"system":"sec-edgar","filing":"0001968202-24-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000093/edgardoc.xml","form_type":"4"}},{"id":1512810,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:04:51.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":727,"price":983.88,"value":715280.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F20","text":"Represents volume-weighted average price of sales of 727 shares of Company stock on May 15, 2024 at prices ranging from $983.21 to $983.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":838200,"source":{"system":"sec-edgar","filing":"0001968202-24-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000093/edgardoc.xml","form_type":"4"}},{"id":1512809,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:04:51.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":303,"price":982.29,"value":297633.87,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F19","text":"Represents volume-weighted average price of sales of 303 shares of Company stock on May 15, 2024 at prices ranging from $982.00 to $982.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":838927,"source":{"system":"sec-edgar","filing":"0001968202-24-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000093/edgardoc.xml","form_type":"4"}},{"id":1512808,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:04:51.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":2283,"price":981.52,"value":2240810.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"Represents volume-weighted average price of sales of 2,283 shares of Company stock on May 15, 2024 at prices ranging from $981.06 to $981.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":839230,"source":{"system":"sec-edgar","filing":"0001968202-24-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000093/edgardoc.xml","form_type":"4"}},{"id":1512807,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:04:51.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":1223,"price":980.72,"value":1199420.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"Represents volume-weighted average price of sales of 1,223 shares of Company stock on May 15, 2024 at prices ranging from $980.11 to $980.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":841513,"source":{"system":"sec-edgar","filing":"0001968202-24-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000093/edgardoc.xml","form_type":"4"}},{"id":1512806,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:04:51.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":504,"price":979.87,"value":493854.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"Represents volume-weighted average price of sales of 504 shares of Company stock on May 15, 2024 at prices ranging from $979.18 to $979.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":842736,"source":{"system":"sec-edgar","filing":"0001968202-24-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000093/edgardoc.xml","form_type":"4"}},{"id":1512805,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:04:51.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":4865,"price":978.44,"value":4760110.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"Represents volume-weighted average price of sales of 4,865 shares of Company stock on May 15, 2024 at prices ranging from $978.01 to $978.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":843240,"source":{"system":"sec-edgar","filing":"0001968202-24-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000093/edgardoc.xml","form_type":"4"}},{"id":1512804,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:04:51.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":9851,"price":977.42,"value":9628564.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"Represents volume-weighted average price of sales of 9,851 shares of Company stock on May 15, 2024 at prices ranging from $977.00 to $977.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":848105,"source":{"system":"sec-edgar","filing":"0001968202-24-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000093/edgardoc.xml","form_type":"4"}},{"id":1512803,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:04:51.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":6885,"price":976.56,"value":6723615.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Represents volume-weighted average price of sales of 6,885 shares of Company stock on May 15, 2024 at prices ranging from $976.00 to $976.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":857956,"source":{"system":"sec-edgar","filing":"0001968202-24-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000093/edgardoc.xml","form_type":"4"}},{"id":1512802,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:04:51.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":5225,"price":975.6,"value":5097510.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents volume-weighted average price of sales of 5,225 shares of Company stock on May 15, 2024 at prices ranging from $975.05 to $975.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":864841,"source":{"system":"sec-edgar","filing":"0001968202-24-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000093/edgardoc.xml","form_type":"4"}},{"id":1512801,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:04:51.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":4778,"price":974.47,"value":4656017.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents volume-weighted average price of sales of 4,778 shares of Company stock on May 15, 2024 at prices ranging from $974.01 to $974.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":870066,"source":{"system":"sec-edgar","filing":"0001968202-24-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000093/edgardoc.xml","form_type":"4"}},{"id":1512800,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:04:51.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":1865,"price":973.43,"value":1815446.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents volume-weighted average price of sales of 1,865 shares of Company stock on May 15, 2024 at prices ranging from $973.00 to $973.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":874844,"source":{"system":"sec-edgar","filing":"0001968202-24-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000093/edgardoc.xml","form_type":"4"}},{"id":1512799,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:04:51.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":784,"price":972.5,"value":762440.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents volume-weighted average price of sales of 784 shares of Company stock on May 15, 2024 at prices ranging from $972.05 to $972.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":876709,"source":{"system":"sec-edgar","filing":"0001968202-24-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000093/edgardoc.xml","form_type":"4"}},{"id":1512798,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:04:51.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":406,"price":971.28,"value":394339.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents volume-weighted average price of sales of 406 shares of Company stock on May 15, 2024 at prices ranging from $971.02 to $971.37. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":877493,"source":{"system":"sec-edgar","filing":"0001968202-24-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000093/edgardoc.xml","form_type":"4"}},{"id":1512797,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:04:51.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":846,"price":970.36,"value":820924.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 846 shares of Company stock on May 15, 2024 at prices ranging from $970.26 to $970.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":877899,"source":{"system":"sec-edgar","filing":"0001968202-24-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000093/edgardoc.xml","form_type":"4"}},{"id":1512796,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:04:51.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":1930,"price":969.14,"value":1870440.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 1,930 shares of Company stock on May 15, 2024 at prices ranging from $969.03 to $969.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":878745,"source":{"system":"sec-edgar","filing":"0001968202-24-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000093/edgardoc.xml","form_type":"4"}},{"id":1512795,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:04:51.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":3387,"price":968.43,"value":3280072.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 3,387 shares of Company stock on May 15, 2024 at prices ranging from $968.06 to $968.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":880675,"source":{"system":"sec-edgar","filing":"0001968202-24-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000093/edgardoc.xml","form_type":"4"}},{"id":1512794,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:04:51.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":1428,"price":967.45,"value":1381518.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 1,428 shares of Company stock on May 15, 2024 at prices ranging from $967.07 to $967.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":884062,"source":{"system":"sec-edgar","filing":"0001968202-24-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000093/edgardoc.xml","form_type":"4"}},{"id":1512793,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:04:51.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":782,"price":966.29,"value":755638.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 782 shares of Company stock on May 15, 2024 at prices ranging from $966.04 to $966.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":885490,"source":{"system":"sec-edgar","filing":"0001968202-24-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000093/edgardoc.xml","form_type":"4"}},{"id":1512792,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-17T20:04:51.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":111,"price":965.69,"value":107191.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 111 shares of Company stock on May 15, 2024 at prices ranging from $965.58 to $965.70. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":886272,"source":{"system":"sec-edgar","filing":"0001968202-24-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000093/edgardoc.xml","form_type":"4"}},{"id":1532399,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-01T20:03:45.000Z","date":"2024-04-29","kind":"gift","planned":false,"acquired":true,"shares":18148,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Children"},"balance_after":18148,"source":{"system":"sec-edgar","filing":"0001883850-24-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000013/edgardoc.xml","form_type":"4"}},{"id":1532398,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-01T20:03:45.000Z","date":"2024-04-29","kind":"gift","planned":false,"acquired":false,"shares":36296,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by 2022 GRAT I"},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001883850-24-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000013/edgardoc.xml","form_type":"4"}},{"id":1532397,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-05-01T20:00:53.000Z","date":"2024-01-02","kind":"sale","planned":true,"acquired":false,"shares":16848,"price":900,"value":15163200.0,"ownership":{"direct":false,"nature":"By Trust for Chldn."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on November 29, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"As investment trustee of trusts for the benefit of the reporting person's children."}],"balance_after":180000,"source":{"system":"sec-edgar","filing":"0001883850-24-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000012/edgardoc.xml","form_type":"4"}},{"id":1635782,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-02-20T21:03:46.000Z","date":"2024-02-15","kind":"exercise","planned":false,"acquired":false,"shares":172723,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":0,"derivative":{"exercise_price":399.66,"expiration_date":"2024-12-16","underlying":"Common Stock","underlying_shares":172723},"source":{"system":"sec-edgar","filing":"0001968202-24-000068","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000068/edgardoc.xml","form_type":"4"}},{"id":1635781,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-02-20T21:03:46.000Z","date":"2024-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":123601,"price":953.83,"value":117894341.83,"ownership":{"direct":true},"balance_after":801608,"source":{"system":"sec-edgar","filing":"0001968202-24-000068","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000068/edgardoc.xml","form_type":"4"}},{"id":1635780,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-02-20T21:03:46.000Z","date":"2024-02-15","kind":"exercise","planned":false,"acquired":true,"shares":172723,"price":399.66,"value":69030474.18,"ownership":{"direct":true},"balance_after":925209,"source":{"system":"sec-edgar","filing":"0001968202-24-000068","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000068/edgardoc.xml","form_type":"4"}},{"id":1689488,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2024-01-04T21:20:19.000Z","date":"2024-01-02","kind":"sale","planned":true,"acquired":false,"shares":16848,"price":900,"value":15163200.0,"ownership":{"direct":false,"nature":"By Trust for Chldn."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on November 29, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"As investment trustee of trusts for the benefit of the reporting person's children."}],"balance_after":180000,"source":{"system":"sec-edgar","filing":"0001883850-24-000007","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000007/edgardoc.xml","form_type":"4"}},{"id":1713168,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"2019 Performance Stock Units","published_at":"2023-12-13T21:05:43.000Z","date":"2023-12-11","kind":"exercise","planned":false,"acquired":false,"shares":25155,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On December 11, 2019, the reporting person was granted performance-based restricted stock units (\"PSUs\") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return (\"TSR\") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 11, 2019, the reporting person was granted performance-based restricted stock units (\"PSUs\") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return (\"TSR\") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 11, 2019, the reporting person was granted performance-based restricted stock units (\"PSUs\") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return (\"TSR\") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On December 11, 2019, the reporting person was granted performance-based restricted stock units (\"PSUs\") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return (\"TSR\") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":25155},"source":{"system":"sec-edgar","filing":"0001883850-23-000095","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000095/edgardoc.xml","form_type":"4"}},{"id":1713167,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2023-12-13T21:05:43.000Z","date":"2023-12-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":12841,"price":844.09,"value":10838959.69,"ownership":{"direct":true},"balance_after":752486,"source":{"system":"sec-edgar","filing":"0001883850-23-000095","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000095/edgardoc.xml","form_type":"4"}},{"id":1713166,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CSO"}}],"security":"Common Stock","published_at":"2023-12-13T21:05:43.000Z","date":"2023-12-11","kind":"exercise","planned":false,"acquired":true,"shares":25155,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 11, 2019, the reporting person was granted performance-based restricted stock units (\"PSUs\") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return (\"TSR\") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended."}],"balance_after":765327,"source":{"system":"sec-edgar","filing":"0001883850-23-000095","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000095/edgardoc.xml","form_type":"4"}},{"id":1938445,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2023-03-27T20:41:56.000Z","date":"2023-03-23","kind":"sale","planned":true,"acquired":false,"shares":400,"price":810.3,"value":324120.0,"ownership":{"direct":false,"nature":"By Trust for Chldn."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on November 29, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"As investment trustee of trusts for the benefit of the reporting person's children."}],"balance_after":196848,"source":{"system":"sec-edgar","filing":"0001883850-23-000062","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000062/edgardoc.xml","form_type":"4"}},{"id":1938444,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2023-03-27T20:41:56.000Z","date":"2023-03-23","kind":"sale","planned":true,"acquired":false,"shares":700,"price":806.47,"value":564529.0,"ownership":{"direct":false,"nature":"By Trust for Chldn."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on November 29, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"As investment trustee of trusts for the benefit of the reporting person's children."}],"balance_after":197248,"source":{"system":"sec-edgar","filing":"0001883850-23-000062","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000062/edgardoc.xml","form_type":"4"}},{"id":1938443,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2023-03-27T20:41:56.000Z","date":"2023-03-23","kind":"sale","planned":true,"acquired":false,"shares":47,"price":805.55,"value":37860.85,"ownership":{"direct":false,"nature":"By Trust for Chldn."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on November 29, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"As investment trustee of trusts for the benefit of the reporting person's children."}],"balance_after":197948,"source":{"system":"sec-edgar","filing":"0001883850-23-000062","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000062/edgardoc.xml","form_type":"4"}},{"id":1938442,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2023-03-27T20:41:56.000Z","date":"2023-03-23","kind":"sale","planned":true,"acquired":false,"shares":254,"price":804.38,"value":204312.52,"ownership":{"direct":false,"nature":"By Trust for Chldn."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on November 29, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 254 shares of Company stock on March 23, 2023 at prices ranging from $804.00 to $804.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 23, 2023 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"As investment trustee of trusts for the benefit of the reporting person's children."}],"balance_after":197995,"source":{"system":"sec-edgar","filing":"0001883850-23-000062","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000062/edgardoc.xml","form_type":"4"}},{"id":1938441,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2023-03-27T20:41:56.000Z","date":"2023-03-23","kind":"sale","planned":true,"acquired":false,"shares":642,"price":803.3,"value":515718.6,"ownership":{"direct":false,"nature":"By Trust for Chldn."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on November 29, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 642 shares of Company stock on March 23, 2023 at prices ranging from $803.01 to $803.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 23, 2023 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"As investment trustee of trusts for the benefit of the reporting person's children."}],"balance_after":198249,"source":{"system":"sec-edgar","filing":"0001883850-23-000062","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000062/edgardoc.xml","form_type":"4"}},{"id":1938440,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2023-03-27T20:41:56.000Z","date":"2023-03-23","kind":"sale","planned":true,"acquired":false,"shares":1237,"price":802.54,"value":992741.98,"ownership":{"direct":false,"nature":"By Trust for Chldn."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on November 29, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 1,237 shares of Company stock on March 23, 2023 at prices ranging from $802.00 to $802.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 23, 2023 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"As investment trustee of trusts for the benefit of the reporting person's children."}],"balance_after":198891,"source":{"system":"sec-edgar","filing":"0001883850-23-000062","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000062/edgardoc.xml","form_type":"4"}},{"id":1938439,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2023-03-27T20:41:56.000Z","date":"2023-03-23","kind":"sale","planned":true,"acquired":false,"shares":122,"price":801.16,"value":97741.52,"ownership":{"direct":false,"nature":"By Trust for Chldn."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on November 29, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 122 shares of Company stock on March 23, 2023 at prices ranging from $801.00 to $801.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 23, 2023 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"As investment trustee of trusts for the benefit of the reporting person's children."}],"balance_after":200128,"source":{"system":"sec-edgar","filing":"0001883850-23-000062","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000062/edgardoc.xml","form_type":"4"}},{"id":1938438,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2023-03-27T20:41:56.000Z","date":"2023-03-23","kind":"sale","planned":true,"acquired":false,"shares":254,"price":800.59,"value":203349.86,"ownership":{"direct":false,"nature":"By Trust for Chldn."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on November 29, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 254 shares of Company stock on March 23, 2023 at prices ranging from $800.52 to $800.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 23, 2023 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"As investment trustee of trusts for the benefit of the reporting person's children."}],"balance_after":200250,"source":{"system":"sec-edgar","filing":"0001883850-23-000062","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000062/edgardoc.xml","form_type":"4"}},{"id":2027183,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2023-02-08T21:15:24.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":13189,"price":800.08,"value":10552255.12,"ownership":{"direct":false,"nature":"By Trust for Chldn."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 13,189 shares of Company stock on February 6, 2023 at prices ranging from $800.00 to $800.48. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"As investment trustee of trusts for the benefit of the reporting person's children."}],"balance_after":200504,"source":{"system":"sec-edgar","filing":"0001883850-23-000044","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000044/edgardoc.xml","form_type":"4"}},{"id":2460222,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-12-23T21:29:47.000Z","date":"2021-12-22","kind":"exercise","acquired":false,"shares":203204,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":0,"derivative":{"exercise_price":270.43,"expiration_date":"2023-12-13","underlying":"Common Stock","underlying_shares":203204},"source":{"system":"sec-edgar","filing":"0001883850-21-000034","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385021000034/edgardoc.xml","form_type":"4"}},{"id":2460221,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-12-23T21:29:47.000Z","date":"2021-12-22","kind":"exercise","acquired":false,"shares":239063,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":0,"derivative":{"exercise_price":179.13,"expiration_date":"2022-12-14","underlying":"Common Stock","underlying_shares":239063},"source":{"system":"sec-edgar","filing":"0001883850-21-000034","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385021000034/edgardoc.xml","form_type":"4"}},{"id":2460220,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2021-12-23T21:29:47.000Z","date":"2021-12-22","kind":"tax_withholding","acquired":false,"shares":150182,"price":610.04,"value":91617027.28,"ownership":{"direct":true},"balance_after":1019653,"source":{"system":"sec-edgar","filing":"0001883850-21-000034","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385021000034/edgardoc.xml","form_type":"4"}},{"id":2460219,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2021-12-23T21:29:47.000Z","date":"2021-12-22","kind":"exercise","acquired":true,"shares":203204,"price":270.43,"value":54952457.72,"ownership":{"direct":true},"balance_after":1169835,"source":{"system":"sec-edgar","filing":"0001883850-21-000034","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385021000034/edgardoc.xml","form_type":"4"}},{"id":2460218,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2021-12-23T21:29:47.000Z","date":"2021-12-22","kind":"tax_withholding","acquired":false,"shares":159915,"price":610.04,"value":97554546.6,"ownership":{"direct":true},"balance_after":966631,"source":{"system":"sec-edgar","filing":"0001883850-21-000034","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385021000034/edgardoc.xml","form_type":"4"}},{"id":2460217,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2021-12-23T21:29:47.000Z","date":"2021-12-22","kind":"exercise","acquired":true,"shares":239063,"price":179.13,"value":42823355.19,"ownership":{"direct":true},"balance_after":1126546,"source":{"system":"sec-edgar","filing":"0001883850-21-000034","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385021000034/edgardoc.xml","form_type":"4"}},{"id":2601254,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2021-08-17T20:13:08.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":2302,"price":626.1,"value":1441282.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 2,302 shares of Company stock on August 16, 2021 at prices ranging from $626.00 to $626.14. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price."}],"balance_after":887483,"source":{"system":"sec-edgar","filing":"0001708138-21-000055","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000055/edgardoc.xml","form_type":"4"}},{"id":2601253,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2021-08-17T20:13:08.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":46925,"price":625.25,"value":29339856.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 46,925 shares of Company stock on August 16, 2021 at prices ranging from $625.00 to $625.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price."}],"balance_after":889785,"source":{"system":"sec-edgar","filing":"0001708138-21-000055","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000055/edgardoc.xml","form_type":"4"}},{"id":2601252,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2021-08-17T20:13:08.000Z","date":"2021-08-13","kind":"sale","acquired":false,"shares":773,"price":625,"value":483125.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":936710,"source":{"system":"sec-edgar","filing":"0001708138-21-000055","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000055/edgardoc.xml","form_type":"4"}},{"id":2612193,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2021-08-06T20:03:49.000Z","date":"2021-06-24","kind":"gift","acquired":false,"shares":211585,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by 2019 GRAT"},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001708138-21-000044","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000044/edgardoc.xml","form_type":"4"}},{"id":2612192,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2021-08-06T20:03:49.000Z","date":"2021-06-24","kind":"gift","acquired":true,"shares":211585,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust for Chldn."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"As investment trustee of trusts for the benefit of the reporting person's children."}],"balance_after":213693,"source":{"system":"sec-edgar","filing":"0001708138-21-000044","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000044/edgardoc.xml","form_type":"4"}},{"id":2612191,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2021-08-06T20:03:49.000Z","date":"2021-08-05","kind":"sale","acquired":false,"shares":50000,"price":600.06,"value":30003000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 50,000 shares of Company stock on August 5, 2021 at prices ranging from $600.00 to $600.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2021 at each separate price."}],"balance_after":937483,"source":{"system":"sec-edgar","filing":"0001708138-21-000044","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000044/edgardoc.xml","form_type":"4"}},{"id":2657873,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Class A Stock","published_at":"2021-06-23T20:02:45.000Z","date":"2021-04-15","kind":"gift","acquired":true,"shares":5383,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Trust for Son"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F15","text":"Class A Stock of Regeneron Pharmaceuticals, Inc. (\"Regeneron\") converts to Common Stock of Regeneron on a one-to-one basis upon certain events or upon election of the shareholder."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"These shares of Class A Stock are presently convertible and such conversion feature does not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F16","text":"These shares of Class A Stock are presently convertible and such conversion feature does not expire."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F17","text":"These shares of Class A Stock are held in a trust for the benefit of the reporting person's child, of which the reporting person is trustee."}],"balance_after":5383,"derivative":{"underlying":"Common Stock","underlying_shares":5383},"source":{"system":"sec-edgar","filing":"0001708138-21-000026","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000026/edgardoc.xml","form_type":"4"}},{"id":2657872,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Class A Stock","published_at":"2021-06-23T20:02:45.000Z","date":"2021-04-15","kind":"gift","acquired":false,"shares":5383,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Son"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F15","text":"Class A Stock of Regeneron Pharmaceuticals, Inc. (\"Regeneron\") converts to Common Stock of Regeneron on a one-to-one basis upon certain events or upon election of the shareholder."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"These shares of Class A Stock are presently convertible and such conversion feature does not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F16","text":"These shares of Class A Stock are presently convertible and such conversion feature does not expire."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F18","text":"These shares of Class A Stock were held in custody for the benefit of the reporting person's child."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5383},"source":{"system":"sec-edgar","filing":"0001708138-21-000026","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000026/edgardoc.xml","form_type":"4"}},{"id":2657871,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Class A Stock","published_at":"2021-06-23T20:02:45.000Z","date":"2021-04-15","kind":"gift","acquired":false,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Daughter"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F15","text":"Class A Stock of Regeneron Pharmaceuticals, Inc. (\"Regeneron\") converts to Common Stock of Regeneron on a one-to-one basis upon certain events or upon election of the shareholder."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"These shares of Class A Stock are presently convertible and such conversion feature does not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F16","text":"These shares of Class A Stock are presently convertible and such conversion feature does not expire."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F18","text":"These shares of Class A Stock were held in custody for the benefit of the reporting person's child."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001708138-21-000026","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000026/edgardoc.xml","form_type":"4"}},{"id":2657870,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Class A Stock","published_at":"2021-06-23T20:02:45.000Z","date":"2021-04-15","kind":"gift","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Tr. for Daughter"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F15","text":"Class A Stock of Regeneron Pharmaceuticals, Inc. (\"Regeneron\") converts to Common Stock of Regeneron on a one-to-one basis upon certain events or upon election of the shareholder."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"These shares of Class A Stock are presently convertible and such conversion feature does not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F16","text":"These shares of Class A Stock are presently convertible and such conversion feature does not expire."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F17","text":"These shares of Class A Stock are held in a trust for the benefit of the reporting person's child, of which the reporting person is trustee."}],"balance_after":14000,"derivative":{"underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001708138-21-000026","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000026/edgardoc.xml","form_type":"4"}},{"id":2657869,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2021-06-23T20:02:45.000Z","date":"2021-06-21","kind":"sale","acquired":false,"shares":2276,"price":543.13,"value":1236163.88,"ownership":{"direct":false,"nature":"By Trust for Chldn."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"Represents volume-weighted average price of sales of 2,276 shares of Company stock on June 21, 2021 at prices ranging from $543.01 to $543.46. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As investment trustee of trusts for the benefit of the reporting person's children."}],"balance_after":2108,"source":{"system":"sec-edgar","filing":"0001708138-21-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000026/edgardoc.xml","form_type":"4"}},{"id":2657868,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2021-06-23T20:02:45.000Z","date":"2021-06-21","kind":"sale","acquired":false,"shares":10514,"price":542.43,"value":5703109.02,"ownership":{"direct":false,"nature":"By Trust for Chldn."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Represents volume-weighted average price of sales of 10,514 shares of Company stock on June 21, 2021 at prices ranging from $542.00 to $542.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As investment trustee of trusts for the benefit of the reporting person's children."}],"balance_after":4384,"source":{"system":"sec-edgar","filing":"0001708138-21-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000026/edgardoc.xml","form_type":"4"}},{"id":2657867,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2021-06-23T20:02:45.000Z","date":"2021-06-21","kind":"sale","acquired":false,"shares":19911,"price":541.44,"value":10780611.84,"ownership":{"direct":false,"nature":"By Trust for Chldn."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents volume-weighted average price of sales of 19,911 shares of Company stock on June 21, 2021 at prices ranging from $541.00 to $541.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As investment trustee of trusts for the benefit of the reporting person's children."}],"balance_after":14898,"source":{"system":"sec-edgar","filing":"0001708138-21-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000026/edgardoc.xml","form_type":"4"}},{"id":2657866,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2021-06-23T20:02:45.000Z","date":"2021-06-21","kind":"sale","acquired":false,"shares":8099,"price":540.61,"value":4378400.39,"ownership":{"direct":false,"nature":"By Trust for Chldn."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents volume-weighted average price of sales of 8,099 shares of Company stock on June 21, 2021 at prices ranging from $540.00 to $540.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As investment trustee of trusts for the benefit of the reporting person's children."}],"balance_after":34809,"source":{"system":"sec-edgar","filing":"0001708138-21-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000026/edgardoc.xml","form_type":"4"}},{"id":2657865,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2021-06-23T20:02:45.000Z","date":"2021-06-21","kind":"sale","acquired":false,"shares":3306,"price":539.66,"value":1784115.96,"ownership":{"direct":false,"nature":"By Trust for Chldn."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents volume-weighted average price of sales of 3,306 shares of Company stock on June 21, 2021 at prices ranging from $539.14 to $539.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As investment trustee of trusts for the benefit of the reporting person's children."}],"balance_after":42908,"source":{"system":"sec-edgar","filing":"0001708138-21-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000026/edgardoc.xml","form_type":"4"}},{"id":2657864,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2021-06-23T20:02:45.000Z","date":"2021-06-21","kind":"sale","acquired":false,"shares":4868,"price":538.54,"value":2621612.72,"ownership":{"direct":false,"nature":"By Trust for Chldn."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents volume-weighted average price of sales of 4,868 shares of Company stock on June 21, 2021 at prices ranging from $538.01 to $538.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As investment trustee of trusts for the benefit of the reporting person's children."}],"balance_after":46214,"source":{"system":"sec-edgar","filing":"0001708138-21-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000026/edgardoc.xml","form_type":"4"}},{"id":2657863,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2021-06-23T20:02:45.000Z","date":"2021-06-21","kind":"sale","acquired":false,"shares":6636,"price":537.61,"value":3567579.96,"ownership":{"direct":false,"nature":"By Trust for Chldn."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents volume-weighted average price of sales of 6,636 shares of Company stock on June 21, 2021 at prices ranging from $537.05 to $537.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As investment trustee of trusts for the benefit of the reporting person's children."}],"balance_after":51082,"source":{"system":"sec-edgar","filing":"0001708138-21-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000026/edgardoc.xml","form_type":"4"}},{"id":2657862,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2021-06-23T20:02:45.000Z","date":"2021-06-21","kind":"sale","acquired":false,"shares":3768,"price":536.37,"value":2021042.16,"ownership":{"direct":false,"nature":"By Trust for Chldn."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 3,768 shares of Company stock on June 21, 2021 at prices ranging from $536.02 to $536.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As investment trustee of trusts for the benefit of the reporting person's children."}],"balance_after":57718,"source":{"system":"sec-edgar","filing":"0001708138-21-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000026/edgardoc.xml","form_type":"4"}},{"id":2657861,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2021-06-23T20:02:45.000Z","date":"2021-06-21","kind":"sale","acquired":false,"shares":4154,"price":535.63,"value":2225007.02,"ownership":{"direct":false,"nature":"By Trust for Chldn."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 4,154 shares of Company stock on June 21, 2021 at prices ranging from $535.05 to $535.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As investment trustee of trusts for the benefit of the reporting person's children."}],"balance_after":61486,"source":{"system":"sec-edgar","filing":"0001708138-21-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000026/edgardoc.xml","form_type":"4"}},{"id":2657860,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2021-06-23T20:02:45.000Z","date":"2021-06-21","kind":"sale","acquired":false,"shares":8236,"price":534.48,"value":4401977.28,"ownership":{"direct":false,"nature":"By Trust for Chldn."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 8,236 shares of Company stock on June 21, 2021 at prices ranging from $534.01 to $534.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As investment trustee of trusts for the benefit of the reporting person's children."}],"balance_after":65640,"source":{"system":"sec-edgar","filing":"0001708138-21-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000026/edgardoc.xml","form_type":"4"}},{"id":2657859,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2021-06-23T20:02:45.000Z","date":"2021-06-21","kind":"sale","acquired":false,"shares":7494,"price":533.66,"value":3999248.04,"ownership":{"direct":false,"nature":"By Trust for Chldn."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 7,494 shares of Company stock on June 21, 2021 at prices ranging from $533.14 to $533.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As investment trustee of trusts for the benefit of the reporting person's children."}],"balance_after":73876,"source":{"system":"sec-edgar","filing":"0001708138-21-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000026/edgardoc.xml","form_type":"4"}},{"id":2657858,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2021-06-23T20:02:45.000Z","date":"2021-06-21","kind":"sale","acquired":false,"shares":738,"price":532.89,"value":393272.82,"ownership":{"direct":false,"nature":"By Trust for Chldn."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 738 shares of Company stock on June 21, 2021 at prices ranging from $532.56 to $532.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As investment trustee of trusts for the benefit of the reporting person's children."}],"balance_after":81370,"source":{"system":"sec-edgar","filing":"0001708138-21-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000026/edgardoc.xml","form_type":"4"}},{"id":2657857,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2021-06-23T20:02:45.000Z","date":"2021-01-12","kind":"gift","acquired":true,"shares":82108,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust for Chldn."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As investment trustee of trusts for the benefit of the reporting person's children."}],"balance_after":82108,"source":{"system":"sec-edgar","filing":"0001708138-21-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000026/edgardoc.xml","form_type":"4"}},{"id":2923367,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Performance Stock Units","published_at":"2021-01-05T21:04:54.000Z","date":"2020-12-31","kind":"grant","acquired":true,"shares":620270,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance restricted stock unit (\"PSU\") represents a contingent right to receive one share of Company stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain total shareholder return (\"TSR\") goals derived from compound annual growth rates of 5.6% to 19.2% over a five-year performance period ending on December 31, 2025 (or in some cases at earlier times). Between 50% and 250% of the target number of 248,108 PSUs may be earned upon achievement of such TSR goals but shall only vest at the end of the five-year performance period if the reporting person's service to the Company continues through such date, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change in control (\"CIC\")). Earned PSUs are subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a CIC."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance restricted stock unit (\"PSU\") represents a contingent right to receive one share of Company stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain total shareholder return (\"TSR\") goals derived from compound annual growth rates of 5.6% to 19.2% over a five-year performance period ending on December 31, 2025 (or in some cases at earlier times). Between 50% and 250% of the target number of 248,108 PSUs may be earned upon achievement of such TSR goals but shall only vest at the end of the five-year performance period if the reporting person's service to the Company continues through such date, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change in control (\"CIC\")). Earned PSUs are subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a CIC."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each performance restricted stock unit (\"PSU\") represents a contingent right to receive one share of Company stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain total shareholder return (\"TSR\") goals derived from compound annual growth rates of 5.6% to 19.2% over a five-year performance period ending on December 31, 2025 (or in some cases at earlier times). Between 50% and 250% of the target number of 248,108 PSUs may be earned upon achievement of such TSR goals but shall only vest at the end of the five-year performance period if the reporting person's service to the Company continues through such date, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change in control (\"CIC\")). Earned PSUs are subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a CIC."}],"balance_after":620270,"derivative":{"underlying":"Common Stock","underlying_shares":620270},"source":{"system":"sec-edgar","filing":"0001104659-21-000904","document":"tm211598-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465921000904/tm211598-2_4seq1.xml","form_type":"4"}},{"id":2928189,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2020-12-31T22:30:53.000Z","date":"2020-12-30","kind":"exercise","acquired":false,"shares":158079,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"With respect to 240,000 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014.  With respect to 158,079 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant."}],"balance_after":0,"derivative":{"exercise_price":52.03,"expiration_date":"2021-12-16","underlying":"Common Stock","underlying_shares":158079},"source":{"system":"sec-edgar","filing":"0001708138-20-000118","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000118/edgardoc.xml","form_type":"4"}},{"id":2928188,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2020-12-31T22:30:53.000Z","date":"2020-12-30","kind":"exercise","acquired":false,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"With respect to 240,000 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014.  With respect to 158,079 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant."}],"balance_after":158079,"derivative":{"exercise_price":52.03,"expiration_date":"2021-12-16","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001708138-20-000118","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000118/edgardoc.xml","form_type":"4"}},{"id":2928187,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2020-12-31T22:30:53.000Z","date":"2020-07-27","kind":"gift","acquired":false,"shares":57465,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by 2018 GRAT"},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001708138-20-000118","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000118/edgardoc.xml","form_type":"4"}},{"id":2928186,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2020-12-31T22:30:53.000Z","date":"2020-12-30","kind":"tax_withholding","acquired":false,"shares":86096,"price":483.25,"value":41605892.0,"ownership":{"direct":true},"balance_after":822207,"source":{"system":"sec-edgar","filing":"0001708138-20-000118","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000118/edgardoc.xml","form_type":"4"}},{"id":2928185,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2020-12-31T22:30:53.000Z","date":"2020-12-30","kind":"exercise","acquired":true,"shares":158079,"price":52.03,"value":8224850.37,"ownership":{"direct":true},"balance_after":908303,"source":{"system":"sec-edgar","filing":"0001708138-20-000118","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000118/edgardoc.xml","form_type":"4"}},{"id":2928184,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70476,"kind":"person","name":"YANCOPOULOS GEORGE","position":1,"cik":"0001226690","reported_name":"YANCOPOULOS GEORGE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Scientific"}}],"security":"Common Stock","published_at":"2020-12-31T22:30:53.000Z","date":"2020-12-30","kind":"tax_withholding","acquired":false,"shares":130714,"price":483.25,"value":63167540.5,"ownership":{"direct":true},"balance_after":750224,"source":{"system":"sec-edgar","filing":"0001708138-20-000118","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000118/edgardoc.xml","form_type":"4"}}],"next_cursor":"2020-12-31T22:30:53.000000Z,2928184"}